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In June 2013 the European Society of Hypertension (ESH) / European Society 
of Cardiology (ESC) published new guidelines for the management of hypertension. 
These are the first European Guidelines for hypertension developed by applying a 
strict “evidence-based” approach using a grading system for the level of evidence and 
the strength of recommendations. Several recommendations in the new guidelines 
deserve careful consideration because they change the way that hypertension is man-
aged is routine clinical practice.
The assessment of the total cardiovascular risk is recommended for deciding when 
to initiate treatment in subjects with confirmed hypertension defined as elevated blood 
pressure >140/90 mmHg (systolic/diastolic). Thus, hypertensive subjects with high or 
very high total cardiovascular risk should promptly start antihypertensive drug treat-
ment once diagnosis is confirmed and the results of the initial evaluation are available. 
On the other hand, hypertensive subjects with lower total cardiovascular risk are advised 
to apply lifestyle modification measures and drug treatment should be initiated after 
several months if blood pressure remains elevated. Treatment of high-normal blood 
pressure (systolic 130-140 mmHg and/or diastolic 80-90 mmHg) is not recommended 
anymore, irrespective of the total cardiovascular risk (low, moderate or high).
The conventional measurement of blood pressure at the doctor’s office remains 
as the main screening tool for hypertension detection. However, increased use and 
specific indications for ambulatory and home blood pressure monitoring are recom-
mended, and directions provided on when to suspect and investigate for white coat 
and masked hypertension. White coat hypertension should be suspected in all subjects 
with grade 1 hypertension, and those with high office blood pressure, no organ damage 
and low total cardiovascular risk. On the other hand, masked hypertension should be 
suspected in all subjects with high-normal office blood pressure, and those with normal 
office blood pressure and asymptomatic organ damage or high total cardiovascular 
risk. White coat hypertension in subjects at low total cardiovascular risk should be 
confirmed with repeated office and out-of-office blood pressure measurements (self-
home or ambulatory blood pressure monitoring) and then regularly followed once or 
twice per year while applying non-pharmacological measures, because of the potential 
to develop sustained hypertension in the following years that will require drug treat-
ment. On the other hand, masked hypertension requires confirmation with repeated 
measurements and then should be treated because it carries similar cardiovascular 
risk as uncontrolled sustained hypertension.
Non-pharmacological measures for blood pressure reduction, as well as the choice 
of drugs for treatment initiation (thiazide diuretics, beta-blockers, calcium channel 
blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers) and 
the use of combinations remain unchanged. The choice of drugs should be tailored 
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according to the individual’s specific indications and contrain-
dications to the antihypertensive drug classes. Other second 
line drugs might be used when combination of the first line 
drugs is not effective or not well tolerated. Treatment might be 
initiated with combination of two drugs in subjects with high 
total cardiovascular risk and blood pressure levels exceeding 
the hypertension threshold by 20 mmHg systolic and/or 10 
mmHg diastolic or more.
The recommended systolic blood pressure goal with treat-
ment now is <140 mmHg for all subjects with hypertension, 
irrespective of their cardiovascular risk (low, moderate, high, 
or very high risk hypertensives, e.g. with diabetes, coronary 
heart disease, stroke, transient ischemic attack, chronic kidney 
disease). In regards to the diastolic blood pressure the recom-
mended goal is <90 mmHg for all subjects with hypertension, 
apart from the diabetics in whom it is <85 mmHg.
In the elderly hypertensives, drug treatment should be initi-
ated at systolic blood pressure levels ≥140 mmHg in those aged 
>65 years and ≥160 mmHg in those >80 years. The treatment 
goal should be <140 mmHg in fit elderly aged <80 years and 
to higher levels in fragile subjects. In those aged >80 years in 
good physical and mental condition the systolic blood pressure 
goal should be 140-150 mmHg.
Shortly after the European guidelines for hypertension 
were published, the American Society of Hypertension to-
gether with the International Society of Hypertension also 
published a clinical practice guidelines document for the 
management of hypertension and the US Joint National Com-
mittee published its 8th report for the management of high 
blood pressure in adults (JNC 8). There are some interesting 
differences among these documents in their recommendations 
and philosophy for hypertension management. However, their 
detailed comparison is rather a matter of intellectual exercise 
for experts and with little clinical relevance for practicing 
physicians. In essence, there is considerable agreement rather 
than disagreement among these guidelines. Thus, the key is-
sue is how to disseminate and implement these guidelines in 
different healthcare systems and in a cost effective manner, 
aiming to improve the poor hypertension control rates in 
the general population and thereby reduce the incidence of 
cardiovascular disease.
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